Business Model Breakdown
How Intelligent Bio Solutions Inc Makes Money
INBS
Market Cap
$11M
Annual Revenue
$3M
Profit Margin
0.0%
Employees
53
The Short Version
Intelligent Bio Solutions Inc. develops and commercializes non-invasive drug screening solutions, primarily utilizing its proprietary fingerprint-based technology. This technology allows for rapid, on-site detection of drug use by analyzing sweat from fingerprints, aiming to provide a more hygienic, convenient, and cost-effective alternative to traditional urine or blood tests. The company currently generates some revenue from other biosolutions, but its significant growth potential lies in the future commercialization of its fingerprint drug screening system, targeting sectors like workplace drug testing, clinical diagnostics, and government agencies.
Where the Revenue Comes From
Existing biosolutions product sales (growing, but currently small)
Future licensing/sales of fingerprint drug screening hardware and recurring consumables (post-FDA approval)
Who buys: Businesses (workplace drug testing), clinical laboratories, government agencies, correctional facilities.
Why It Works (Competitive Advantages)
- ✔Proprietary non-invasive fingerprint drug screening technology (Intangible Assets/IP)
- ✔Potential for rapid, on-site testing with high accuracy
- ✔Hygienic and user-friendly testing experience compared to traditional methods
Economic Moat: Narrow (Intangible Assets/IP (patented fingerprint technology))
What Our Analysis Says
DVR Score as of April 9, 2026
Intelligent Bio Solutions Inc. (INBS) continues to be a high-risk, high-reward investment, with an increased score reflecting material progress in its core drug screening technology. The completion of initial FDA clinical studies and commencement of Phase 2 are significant de-risking events, advancing its proprietary fingerprint technology toward commercialization. This strengthens its long-term potential for market leadership and 10x growth. However, the company remains unprofitable with implied negative cash flow, faces potential dilution from an ATM filing, and lacks detailed financial transparency. While executive equity grants show alignment, the investment remains speculative, heavily reliant on successful regulatory approval and subsequent commercial adoption to justify its valuation.